title: Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk.
abstract: BACKGROUND
  Anandamide (AEA) activates both cannabinoid CB(1) and TRPV1 receptors, which are expressed on cultured dorsal root ganglion neurones. Increased levels of nerve growth factor (NGF) are associated with chronic pain states.
  
  
  METHODS
  The aim of this study was to compare of the effects of AEA on CB(1) receptor signalling and TRPV1-CB(1) crosstalk in low and high concentrations of NGF, using voltage-clamp electrophysiology and Fura-2 calcium imaging.
  
  
  RESULTS
  Chronic exposure to high NGF (200 ng ml(-1)) as compared to low NGF (20 ng ml(-1)) increases the proportion of neurones that exhibit an inward current in response to AEA (1 microM), from 7 to 29%. In contrast, inhibition of voltage-gated calcium currents by AEA is not significantly different in low NGF (33+/-9%, compared to high NGF 28+/-6%). Crosstalk between CB and TRPV1 receptors is modulated by exposure to high NGF. In low NGF, exposure to the CB(1) receptor antagonist, SR141716A, (100 nM) increases the percentage of neurones in which AEA elicits an increase in [Ca(2+)](i), from 10 to 23%. In high NGF, the antagonist does not alter the percentage of responders (33 to 30%). In low NGF, exposure to the CB receptor agonist, WIN55 (1 microM) reduces capsaicin-mediated increases in [Ca(2+)](i) to 28+/-8% of control as compared to an enhancement to 172+/-26% of control observed in high NGF.
  
  
  CONCLUSIONS
  We conclude that cannabinoid-mediated modulation of TRPV1 receptor activation is altered after exposure to high NGF.
authors: Medical Faculty, University of Calgary, Calgary, Canada.
authors: R M
authors: RM
authors: Evans
authors: R H
authors: RH
authors: Scott
authors: R A
authors: RA
authors: Ross
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001095:Arachidonic Acids / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000494:pharmacology*; D002478:Cells, Cultured; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D063388:Endocannabinoids; D016257:Fura-2; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D020932:Nerve Growth Factor / Q000008:administration & dosage / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D018408:Patch-Clamp Techniques; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D050916:TRPV Cation Channels / Q000187:drug effects* / Q000378:metabolism
chemical_list: D001095:Arachidonic Acids; D015220:Calcium Channels; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D050916:TRPV Cation Channels; C494484:TRPV1 receptor; D020932:Nerve Growth Factor; D002118:Calcium; D016257:Fura-2; C078814:anandamide
references: J Neurosci. 1995 Jul;15(7 Pt 1):4918-26
references: 7623122
references: Brain Res Mol Brain Res. 1994 Aug;25(1-2):73-9
references: 7984055
references: J Neurosci. 1999 Oct 15;19(20):8765-77
references: 10516296
references: BMC Neurosci. 2005;6:4
references: 15667652
references: J Neurosci. 2005 May 11;25(19):4835-43
references: 15888659
references: EMBO J. 2005 Dec 21;24(24):4211-23
references: 16319926
references: Trends Pharmacol Sci. 2006 Feb;27(2):85-91
references: 16376998
references: Neurosci Lett. 2006 May 15;399(1-2):51-6
references: 16481104
references: Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8
references: 16849427
references: J Biol Chem. 2006 Oct 27;281(43):32879-90
references: 16954222
references: Receptors Channels. 1999;6(5):363-74
references: 10551268
references: Mol Cell Neurosci. 2000 Jun;15(6):510-21
references: 10860578
references: Neuroscience. 2000;100(4):685-8
references: 11036202
references: Neuropharmacology. 2001;40(2):221-32
references: 11114401
references: Br J Pharmacol. 2001 Feb;132(3):631-40
references: 11159715
references: J Neurosci. 2001 Feb 15;21(4):1104-9
references: 11160380
references: Br J Pharmacol. 2001 Mar;132(5):969-71
references: 11226126
references: Nature. 2001 Jun 21;411(6840):957-62
references: 11418861
references: Br J Pharmacol. 2002 Jan;135(1):21-4
references: 11786475
references: Neuroscience. 2002;110(4):747-53
references: 11934481
references: Pain. 2002 May;97(1-2):11-21
references: 12031775
references: Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):101-21
references: 12052030
references: Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):243-56
references: 12052040
references: Neuropharmacology. 2002 Jun;42(7):966-75
references: 12069907
references: Neuroscience. 2002;115(2):613-25
references: 12421626
references: Cell Mol Life Sci. 2003 Mar;60(3):607-16
references: 12737320
references: Neuroscience. 2003;119(3):803-12
references: 12809701
references: Eur J Neurosci. 2003 Jun;17(12):2611-8
references: 12823468
references: J Physiol. 2003 Sep 1;551(Pt 2):433-46
references: 12815188
references: Br J Pharmacol. 2003 Nov;140(5):790-801
references: 14517174
references: Anesthesiology. 2003 Dec;99(6):1391-401
references: 14639155
references: J Neurosci. 2004 Feb 18;24(7):1744-53
references: 14973253
references: Cell Calcium. 2004 May;35(5):471-8
references: 15003856
references: Br J Pharmacol. 2004 Apr;141(7):1223-33
references: 15023857
references: Neuron. 1988 Dec;1(10):973-81
references: 3272159
references: Pain. 1998 Mar;75(1):111-9
references: 9539680